Good news - we have updated our site profiles

We are pleased to announce that we have updated our online profiles, as part of our commitment to improving the clinical trial experience.  Our updated profiles are now available for both investigators and site staff. Learn more

Our updated profile means

What is Investigator Databank?

The Investigator Databank is a global collaboration between Janssen, Lilly, Merck, Pfizer and Novartis (with more companies to come) to share investigator information that each company has on file with one another. Investigator Databank aims to reduce administrative burden for investigators and to increase visibility of qualified investigators to research sponsors.

“Helps the busy sites like us to use a centralized data bank to timely update the site information. I wish other pharmaceutical companies will also support this effort.”

Investigator, USA

How can the Investigator Databank benefit Investigators?

  • Decreases administrative burden for investigators.
  • Expands investigator access to clinical research opportunities.
  • Allows investigators to view, edit, and comment on their profile via website.

How can I get started?

As a first step, you can search to see if any of the Investigator Databank industry members or have a record of you or your site on file. If found, all you need to do is “opt-in” to start sharing with the Investigator Databank and be taken to your profile where you can view, edit, and comment on information from industry member’s clinical trial management systems.

There is no charge to investigators or their institutions to opt-in to the Investigator Databank and to create a profile. Industry member companies share the financial support for development and access to the Databank.

Search for my records

What are the benefits to industry?

Member pharma companies benefit from the following

  • More informed protocol planning and country selection
  • Increased access to investigators for feasibility and site identification
  • More rapid recruitment through better matching of investigators to protocols
  • Faster start-up from sharing of standard documents